<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05000411</url>
  </required_header>
  <id_info>
    <org_study_id>CDDP</org_study_id>
    <nct_id>NCT05000411</nct_id>
  </id_info>
  <brief_title>The Impact of Compound Danshen Dropping Pills (CDDP) on the Post-myocardial Infarction Ventricular Remodeling</brief_title>
  <official_title>The Impact of Traditional Chinese Medicine, Compound Danshen Dropping Pills (CDDP) on the Post-myocardial Infarction Ventricular Remodeling: A Multicentre, Randomized, Double-blind, Placebo-controlled, Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy and safety of compound Danshen dropping pills&#xD;
      (CDDP) in improving ventricular remodeling and cardiac function after acute anterior wall&#xD;
      ST-Elevation myocardial infarction(STEMI). 268 patients with acute anterior wall STEMI after&#xD;
      primary Percutaneous Coronary Intervention (pPCI) are randomly assigned 1:1 to CDDP&#xD;
      group(n=134) and control group(n=134) with follow-up of 24 weeks. Both groups are treated&#xD;
      with standard therapy of STEMI, with the CDDP group administrating 20 tablets of CDDP before&#xD;
      pPCI and 10 tablets three times a day after pPCI and the control group treated with placebo&#xD;
      at the same time. The primary endpoint is 24-week echocardiographic including left ventricle&#xD;
      ejection fraction (LVEF) , left ventricular end-diastolic volume index (LVEDVI) and left&#xD;
      ventricular end-systolic volume index (LVESVI).The secondary endpoint is the change in N&#xD;
      terminal pro-B-type natriuretic peptide（NT-proBNP ）level, arrhythmia and cardiovascular&#xD;
      events (death, cardiac arrest or cardiopulmonary resuscitation, hospitalization due to heart&#xD;
      failure or angina pectoris).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Progressive ventricular remodeling after acute anterior wall myocardial&#xD;
      infarction（MI）is an important factor in the occurrence and death of heart failure.&#xD;
      Angiotensin converting enzyme inhibitors and beta-blockers can ameliorate post-MI ventricular&#xD;
      remodeling, but high-dose therapy can't be tolerable because of hemodynamic instability in&#xD;
      the early stage of acute mycardial infarction（AMI）. It is known that traditional Chinese&#xD;
      medicine, compound Danshen dropping pills (CDDP) exerts protective effect on microcirculatory&#xD;
      disturbance caused by ischemia-reperfusion injury and improves energy metabolism after acute&#xD;
      myocardial ischemia. Experimental studies have shown CDDP may attenuate ventricular&#xD;
      remodeling after myocardial infarction.&#xD;
&#xD;
      Methods：This study is designed to evaluate the efficacy and safety of CDDP in improving&#xD;
      ventricular remodeling and cardiac function after acute anterior wall ST-Elevation MI(STEMI).&#xD;
      268 patients with acute anterior wall STEMI after primary Percutaneous Coronary Intervention&#xD;
      (pPCI) are randomly assigned 1:1 to CDDP group(n=134) and control group(n=134) with follow-up&#xD;
      of 24 weeks. Both groups are treated with standard therapy of STEMI, with the CDDP group&#xD;
      administrating 20 tablets of CDDP before pPCI and 10 tablets three times a day after pPCI and&#xD;
      the control group treated with placebo at the same time. The primary endpoint is 24-week&#xD;
      echocardiographic including left ventricle ejection fraction (LVEF) , left ventricular&#xD;
      end-diastolic volume index (LVEDVI) and left ventricular end-systolic volume index&#xD;
      (LVESVI).The secondary endpoint is the change in N terminal pro-B-type natriuretic&#xD;
      peptide（NT-proBNP） level, arrhythmia and cardiovascular events (death, cardiac arrest or&#xD;
      cardiopulmonary resuscitation, hospitalization due to heart failure or angina pectoris).&#xD;
&#xD;
      Discussion：This is the first prospective study that will demonstrate the impact of CDDP on&#xD;
      ventricular remodeling and cardiac function in patients treated with pPCI for a first acute&#xD;
      anterior wall STEMI .This study may provide novel insights of Traditional Chinese Medicine ,&#xD;
      CDDP to improve ventricular remodeling.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 25, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 25, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ultrasonic cardiogram：left ventricle ejection fraction (LVEF)</measure>
    <time_frame>Week 24</time_frame>
    <description>LVEF refers to the percentage of stroke output to left ventricular end-diastolic volume and it can be examined by ultrasonic cardiogram.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ultrasonic cardiogram：left ventricular end-diastolic volume index (LVEDVI)</measure>
    <time_frame>Week 24</time_frame>
    <description>LVEDVI（ml/m2）=left ventricular end-diastolic volume（ml）/body surface area（m2）. It can be examined by ultrasonic cardiogram.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ultrasonic cardiogram：left ventricular end-systolic volume index (LVESVI)</measure>
    <time_frame>Week 24</time_frame>
    <description>LVESVI（ml/m2）=left ventricular end-systolic volume（ml）/body surface area（m2）. It can be examined by ultrasonic cardiogram.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>N terminal pro-B-type natriuretic peptide（NT-proBNP ）decline level</measure>
    <time_frame>Day 0/ Day 3/ Day 7/ Week 4/ Week 24/ Week 48</time_frame>
    <description>N terminal pro-B-type natriuretic peptide（NT-proBNP ）is obtained by blood test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse cardiovascular events</measure>
    <time_frame>Day 0 to Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">268</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Compound Danshen Dropping Pills (CDDP)</intervention_name>
    <description>The patients in this group are treated with 20 tablets of Compound Danshen Dropping Pills (CDDP) before primary Percutaneous Coronary Intervention (pPCI) and 10 tablets three times a day after pPCI.</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The patients in this group take 20 tablets of placebo before primary Percutaneous Coronary Intervention (pPCI) and 10 tablets three times a day after pPCI .</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18-75 years, gender unlimited;&#xD;
&#xD;
          2. According to the guidelines for diagnosis and treatment of acute ST segment elevation&#xD;
             myocardial infarction (2019), patients with acute anterior ST segment elevation&#xD;
             myocardial infarction were diagnosed;&#xD;
&#xD;
          3. Patients with primary acute myocardial infarction;&#xD;
&#xD;
          4. Patients who completed PCI reperfusion treatment within 12 hours after the onset of&#xD;
             the disease;&#xD;
&#xD;
          5. Subjects participated in the study voluntarily and signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with previous cardiac insufficiency caused by other diseases (valvular heart&#xD;
             disease, congenital heart disease, pericardial disease, arrhythmia, other non cardiac&#xD;
             causes);&#xD;
&#xD;
          2. The patients underwent coronary artery bypass graft（CABG） within 12 weeks;&#xD;
&#xD;
          3. Patients undergoing cardiac resynchronization;&#xD;
&#xD;
          4. Patients with left ventricular outflow tract obstruction;&#xD;
&#xD;
          5. Patients with myocarditis;&#xD;
&#xD;
          6. Patients with uncontrolled severe arrhythmia;&#xD;
&#xD;
          7. Patients with aortic aneurysm;&#xD;
&#xD;
          8. Patients with serious liver, kidney, blood system, mental disease or systemic disease;&#xD;
&#xD;
          9. Significant liver and kidney dysfunction (ALT &gt; 2.0 times the upper limit of normal&#xD;
             value; creatinine &gt; 1.5 times the upper limit of normal value);&#xD;
&#xD;
         10. Patients with serum potassium &gt; 5.5mmol/l;&#xD;
&#xD;
         11. Uncontrolled hypertension (higher than 180 / 110mmhg);&#xD;
&#xD;
         12. Pregnant or lactating women;&#xD;
&#xD;
         13. Patients allergic to compound Danshen Dropping Pills; 1&#xD;
&#xD;
         14. Patients participating in clinical studies of other drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Liansheng Wang</last_name>
    <phone>+86 13390787111</phone>
    <email>drlswang@njmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liansheng Wang, Doctor</last_name>
      <phone>025 68303125</phone>
      <email>drlswang@njmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Ventricular Remodeling</keyword>
  <keyword>CDDP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

